Gut Bacterial Composition for Long-Remission IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune disorders, particularly inflammatory bowel disease (IBD), are sub-optimal with high adverse effects, low compliance, and lack effective solutions for maintaining extended periods of disease-free remission, while the therapeutic potential of gut bacteria remains unresolved.
Innovation Solution
Development of compositions comprising the bacterial strain Intestinicoccus colisanans, which enhances gut barrier function by increasing mucin quality and integrity of tight junction proteins, reducing inflammation, and inhibiting STAT3 signaling, thereby treating and preventing inflammatory and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional treatments for IBD are used, then inflammation is reduced, but adverse effects increase and compliance decreases
Solution Approach 1:
The patent introduces Intestinicoccus colisanans as an intermediary biological agent that mediates the treatment of IBD. This probiotic bacterium acts as a living mediator that modulates the immune system and gut barrier function, reducing inflammation through natural biological mechanisms rather than direct pharmacological intervention, thereby minimizing adverse effects while maintaining therapeutic efficacy
Solution Approach 2:
The treatment leverages the body's own biological systems by introducing beneficial bacteria that work synergistically with host immune cells. The I. colisanans strain promotes regulatory T cell development and enhances gut barrier function through naturally occurring mechanisms, allowing the body to treat itself using its inherent biological capabilities rather than relying on external pharmaceutical agents with known side effect profiles
2Object-affected harmful factors
If conventional IBD therapies are administered, then disease symptoms are managed, but remission duration remains short
Solution Approach 1:
The patent employs preliminary action by introducing I. colisanans to prevent disease progression and induce long-term remission before symptoms fully manifest or recur. The probiotic works proactively to maintain gut barrier integrity and regulate immune responses, preventing the cyclical nature of IBD flares and achieving extended disease-free periods through preventive biological modulation rather than reactive symptom management
Solution Approach 2:
The treatment establishes continuous beneficial action through persistent colonization of I. colisanans in the gut microbiota. Once established, the probiotic strain continuously performs useful functions including maintaining tight junction protein integrity, producing anti-inflammatory metabolites, and regulating immune cell activity, thereby sustaining long-term remission without requiring frequent intervention cycles
3Productivity
If aggressive IBD treatments are used, then disease progression is slowed, but surgery requirements increase
Solution Approach 1:
The patent converts the harmful imbalance in gut microbiota composition into a beneficial therapeutic opportunity. By introducing I. colisanans to correct dysbiosis and restore microbial equilibrium, the treatment addresses the root cause of inflammation rather than merely suppressing symptoms with aggressive medications. This approach prevents the need for progressive escalation to surgical intervention by maintaining disease control through gentle biological restoration
Data Source
AI summary
Disclosed are therapeutic compositions comprising bacterial strains and methods for the treatment or prevention of disease. More particularly, the present invention also discloses compositions comprising bacterial strains isolated from the human digestive tract and their use in the treatment or prevention of inflammatory and autoimmune disorders.